$1.72
3.61% yesterday
NYSE, Dec 24, 07:01 pm CET
ISIN
US1420381089
Symbol
CRBU

Caribou Biosciences Stock price

$1.72
-0.15 8.02% 1M
+0.31 21.99% 6M
+0.13 8.18% YTD
+0.03 1.78% 1Y
-4.44 72.08% 3Y
-14.60 89.46% 5Y
-14.60 89.46% 10Y
-14.60 89.46% 20Y
NYSE, Closing price Wed, Dec 24 2025
+0.06 3.61%
ISIN
US1420381089
Symbol
CRBU
Industry

Key metrics

Basic
Market capitalization
$160.8m
Enterprise Value
$13.5m
Net debt
positive
Cash
$147.3m
Shares outstanding
93.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
17.3 | 16.2
EV/Sales
1.5 | 1.4
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
80.7%
Return on Equity
-59.0%
ROCE
-87.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$9.3m | $9.9m
EBITDA
$-142.5m | $-146.2m
EBIT
$-146.6m | $-154.1m
Net Income
$-157.1m | $-153.3m
Free Cash Flow
$-127.7m
Growth (TTM | estimate)
Revenue
-19.0% | -0.6%
EBITDA
11.9% | 10.2%
EBIT
11.2% | 7.5%
Net Income
-6.1% | -2.8%
Free Cash Flow
2.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,532.8% | -1,471.6%
EBIT
-1,577.4%
Net
-1,690.5% | -1,543.9%
Free Cash Flow
-1,374.2%
More
EPS
$-1.7
FCF per Share
$-1.4
Short interest
6.9%
Employees
147
Rev per Employee
$70.0k
Show more

Is Caribou Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Caribou Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Caribou Biosciences forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Caribou Biosciences forecast:

Buy
93%
Hold
7%

Financial data from Caribou Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
9.30 9.30
19% 19%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
13% 13%
428%
- Research and Development Expense 116 116
11% 11%
1,248%
-142 -142
12% 12%
-1,532%
- Depreciation and Amortization 4.15 4.15
19% 19%
45%
EBIT (Operating Income) EBIT -147 -147
11% 11%
-1,577%
Net Profit -157 -157
6% 6%
-1,690%

In millions USD.

Don't miss a Thing! We will send you all news about Caribou Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Caribou Biosciences Stock News

Neutral
GlobeNewsWire
24 days ago
BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will host an expert physician panel discussion during an ancillary event at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. The session will focus on how vispa-cel, Caribou's a...
Neutral
GlobeNewsWire
about one month ago
Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class allogeneic CAR-T cell therapy for LBCL CB-011 CaMMouflage phase 1 data demonstrate deep, durable responses and manageable safety, highlighting its potential as a best-in-class allogeneic CAR-T cel...
Neutral
GlobeNewsWire
about 2 months ago
BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:
More Caribou Biosciences News

Company Profile

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Head office United States
CEO Rachel Haurwitz
Employees 147
Founded 2011
Website www.cariboubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today